Your session is about to expire
← Back to Search
ABT-263 + Rituximab for Blood Cancers
Study Summary
This trial is testing a new combination therapy for lymphoproliferative disorders. It will last up to 12 years, with participants being monitored quarterly.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 60 Patients • NCT00481091Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a CD20-positive lymphoma with a measurable lesion.I do not have any uncontrolled conditions like a serious fungal infection or recent fever with low white blood cells.I have tested positive for HIV, Hepatitis B, or Hepatitis C, but can join if I'm only a carrier of Hepatitis B.I have a bleeding condition or have had significant bleeding in the past 6 months.My blood counts meet the required levels for treatment.I am not pregnant, and if capable of becoming pregnant, I am using effective birth control.I had a stem cell transplant over 6 months ago and my blood counts meet the required levels.My kidney, liver, and blood clotting functions are within normal ranges.I don't have severe health issues that could affect my trial participation.I haven't taken steroids, aspirin, certain infection drugs, cancer immunotherapy, or any cancer treatment in the specified times before starting the study drug.I am currently pregnant or breastfeeding.I am fully active or can carry out light work.My platelet count is above 25,000/mm3 without transfusions.
- Group 1: ABT-263 + rituximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment available for this research endeavor?
"Unfortunately, no further patients are being sought for this trial. Initially posted on July 21st of 2009 and last edited June 3rd 2022, it is currently closed to new participants. However, there are 3529 studies recruiting individuals with lymphoma diffuse and 417 clinical trials seeking volunteers for ABT-263."
How many distinct venues are managing this clinical experiment?
"This medical trial has been established in 4 different sites, such as the University of Arizona Cancer Center - North Campus /ID# 16721 in Tucson, Stanford University School of Med /ID# 9782 in Stanford and Univ of Wisconsin Hosp/Clinics /ID# 21701 in Madison."
What medical afflictions has ABT-263 been documented to address?
"ABT-263 is a commonly used medicine for treating DLBCL and has shown promise in managing b-cell lymphomas, polyangium, and pemphigus vulgaris."
What is the scope of participants receiving treatment in this experiment?
"At this moment, the recruitment for this clinical trial has closed. It was first listed on July 21st 2009 and last updated 3rd June 2022. If you are in search of other trials, 3529 medical studies recruiting patients with diffuse lymphoma and 417 looking to enrol ABT-263 subjects remain active presently."
Has the Food & Drug Administration greenlit ABT-263?
"With limited data affirming ABT-263's efficacy and safety, our team at Power estimated its risk level to be 1 on a scale of one to three."
What has been revealed through additional research of ABT-263?
"ABT-263 was first evaluated in 1993 at the NIH Clinical Center, 9000 Rockville Pike. Since then there have been 820 successful studies and 417 that are still recruiting participants - many of which take place at medical centers located in Tucson, Arizona."
How may I become involved in this particular clinical investigation?
"Eligible applicants must possess diffuse lymphoma and be between the ages of 18-99. This medical experiment is looking to recruit a total of 29 participants."
Is the age-range for this trial limited to individuals below 20 years old?
"This trial seeks to enrol individuals aged 18-99. For those under 18, there are 665 prospective studies while 3,552 exist for seniors over 65 years old."
Share this study with friends
Copy Link
Messenger